New drug trial aims to control dangerous blood clots
Disease control
Not yet recruiting
This early-stage trial is testing a new drug called TGD001 for people experiencing acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and related blood clotting disorders. The study will first find a safe dose, then test how well it works when given alon…
Phase: PHASE1, PHASE2 • Sponsor: TargED Biopharmaceuticals B.V. • Aim: Disease control
Last updated Apr 02, 2026 02:57 UTC